Patent: 6,581,606
✉ Email this page to a colleague
Summary for Patent: 6,581,606
Title: | Method, apparatus and system for use in treating patient with a drug having an antineoplastic effect to optimize therapy and prevent an adverse drug response |
Abstract: | A method, apparatus and system for use in treating a patient receiving an antineoplastic drug to optimize therapy and prevent an adverse drug response. This system employs surrogate markers or indicators including blood levels of the antineoplastic drug to determine the next required dose for a patient. Since the surrogate markers are employed as a percent change in status, virtually any indicator can be used. Surrogate markers could include any measure of the effectiveness of the antineoplastic drug\'s action. Given the effectiveness of the antineoplastic drug\'s action relative to the surrogate markers, a change in antineoplastic drug dose is calculated by the system. Conversely, by employing this system, one could determine the expected result of the antineoplastic drug dose change on the surrogate markers. |
Inventor(s): | Kutzko; John D. (Nokomis, FL), McMichael; John P. (Wexford, PA), Singer; Michaeal G. (Harrisville, MI) |
Assignee: | The Rx Files Corporation (Nokomis, FL) |
Application Number: | 09/817,906 |
Patent Claims: | see list of patent claims |
Details for Patent 6,581,606
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Recordati Rare Diseases, Inc. | ELSPAR | asparaginase | For Injection | 101063 | 01/10/1978 | ⤷ Try a Trial | 2019-07-06 |
Merck Teknika Llc | TICE BCG | bcg live | For Injection | 102821 | 06/21/1989 | ⤷ Try a Trial | 2019-07-06 |
Merck Sharp & Dohme Corp. | INTRON A | interferon alfa-2b | For Injection | 103132 | 06/04/1986 | ⤷ Try a Trial | 2019-07-06 |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |